Semaglutide is the active compound behind Ozempic and Wegovy — probably the most-discussed drug in medicine right now. This guide cuts through the hype and covers the actual mechanism, what the clinical trials showed, how the dosing works, and where researchers source it. No fluff.
Semaglutide is a GLP-1 receptor agonist — a synthetic peptide that mimics glucagon-like peptide-1, a hormone naturally released by your gut after eating. It was developed by Novo Nordisk and approved by the FDA as Ozempic (type 2 diabetes) in 2017 and Wegovy (chronic weight management) in 2021.
In the research world, semaglutide is studied for its effects on appetite regulation, metabolic function, cardiovascular protection, and neuroinflammation. The long half-life (~7 days) means once-weekly dosing, which is one of its major practical advantages over older GLP-1 compounds.
GLP-1 is normally released from L-cells in your small intestine after a meal. It tells the brain you're full, slows gastric emptying so food moves through more slowly, and stimulates insulin release from the pancreas in a glucose-dependent way (meaning it only triggers insulin when blood sugar is actually elevated — no hypoglycemia risk).
Semaglutide is an analogue of native GLP-1 with two key modifications: a C18 fatty acid chain attached via a linker (allowing albumin binding and extending half-life) and substitution of alanine with Aib at position 2 (preventing DPP-4 enzyme degradation).
Semaglutide has one of the most robust clinical evidence bases of any compound in this category. Key trials:
| Trial | Dose | Duration | Outcome |
|---|---|---|---|
| STEP-1 | 2.4mg/week | 68 weeks | 14.9% mean body weight loss |
| STEP-2 (T2D) | 2.4mg/week | 68 weeks | 9.6% mean body weight loss |
| STEP-4 | 2.4mg/week | 48 weeks | 7.9% additional loss vs placebo after maintenance phase |
| SUSTAIN-6 | 0.5–1mg/week | 104 weeks | 26% reduction in MACE (cardiovascular events) |
| SELECT | 2.4mg/week | ~3 years | 20% reduction in cardiovascular events in overweight/obese non-diabetics |
The SELECT trial (2023) was particularly notable — it demonstrated cardiovascular benefit in people without diabetes, the first GLP-1 trial to do so at scale.
Clinical and research protocols follow a gradual escalation to minimize GI side effects. Rushing the titration schedule is the most common mistake — GI symptoms are dose-dependent and mostly resolve if you go slow.
| Phase | Weekly Dose | Notes |
|---|---|---|
| Weeks 1–4 | 0.25mg | Tolerability phase — don't skip this |
| Weeks 5–8 | 0.5mg | Most research subjects see initial effects here |
| Weeks 9–12 | 1.0mg | Significant appetite reduction |
| Weeks 13–16 | 1.7mg | Maintenance/escalation |
| Weeks 17+ | 2.4mg | Target dose for weight management research |
The most common side effects in trials are gastrointestinal and dose-dependent. They're most pronounced during escalation phases and typically diminish as the body adjusts.
The natural comparison question. Short version: tirzepatide outperforms semaglutide on weight loss in head-to-head data, but both are clinically meaningful. Semaglutide has a longer track record and more real-world safety data at this point.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Avg. weight loss | ~15% | ~21–22% |
| Half-life | ~7 days | ~5 days |
| Head-to-head | — | Superior (SURPASS-6) |
| Track record | Longer (since 2017) | Newer (2022) |
For a full breakdown, see the Semaglutide vs Tirzepatide comparison.
For research purposes, semaglutide is available from COA-verified vendors. Key criteria: third-party tested certificate of analysis, proper lyophilized powder form, and cold-chain shipping.
Both vendors below provide third-party tested semaglutide. Use the discount codes to save on your research order.